Caudate volume as an outcome measure in clinical trials for Huntington's disease: A pilot study

Brain Research Bulletin

Volumn 62, Issue 2, 2003, Pages 137-141

  Aylward, E H ^a,b   Rosenblatt, A ^b   Field, K ^a   Yallapragada, V ^a   Kieburtz, K ^c   McDermott, M ^c   Raymond, L A ^d   Almqvist, E W ^d   Hayden, M ^d   Ross, C A ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Basal ganglia; Longitudinal; MRI; Neuroimaging

Indexed keywords

REMACEMIDE; UBIQUINONE;

ARTICLE; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 10744220393     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2003.09.005     Document Type: Article

References (20)

1. Aylward E.H., Codori A.M., Barta P.E., Pearlson G.P., Harris G.J., Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease. Arch. Neurol. 53:1996;1293-1296.
2. Aylward E.H., Codori A.M., Rosenblatt A., Sherr M., Brandt J., Stine O.C., Barta P.E., Pearlson G.D., Ross C.A. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov. Disord. 15:2000;552-560.
3. Aylward E.H., Li Q., Stine O.C., Ranen N., Sherr M., Barta P.E., Bylsma F.W., Pearlson G.D., Ross C.A. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology. 48:1997;394-399.
4. Bannan P.E., Graham D.I., Lees K.R., McCulloch J. Neuroprotective effect of Remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res. 664:1994;271-275.
5. Black M.A., Tremblay R., Mealing G., Ray R., Durkin P., Whitefield J.F., Blosser J., Morley P. N-Methy-D-aspartate or glutamate-mediated toxicity in cultured rat cortical neurons is antagonized by FPL 15896AR. J. Neurochem. 65:1995;2170-2177.
6. Buchanan R.W., Vladar K., Barta P.E., Pearlson G.D. Structural evaluation of the prefrontal cortex in schizophrenia. Am. J. Psychiatry. 155:1998;1049-1055.
7. 10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22:2002;1592-1629.
8. Gunning-Dixon F.M., Head D., McQuain J., Acker J.D., Raz N. Differential aging of the human striatum: a prospective MR imaging study. AJNR Am. J. Neuroradiol. 19:1998;1501-1507.
9. Harris G., Pearlson G., Peyser C., Aylward E., Roberts J., Barta P., Chase G., Folstein S. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann. Neurol. 31:1992;69-75.
10. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., Hickey C., Orme C., Claude K., Sotack J., Greenamyre J.T., Dunn C., Shoulson I. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. 11:1996;273-277.
11. Kremer B., Clark C.M., Almqvist E.W., Raymond L.A., Graf P., Jacova C., Mezei M., Hardy M.A., Snow B., Martin W., Hayden M.R. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology. 53:1999;1000-1011.
12. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry. 49:2001;487-499.
13. Margolis R.L., Ross C.A. Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends Mol. Med. 7:2001;479-482.
14. Myers R.H., Vonsattel J.P., Stevens T.J., Cupples L.A., Richardson E.P., Martin J.B., Bird E.D. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology. 38:1988;341-347.
15. Rosas H.D., Koroshetz W.J., Jenkins B.G., Chen Y.I., Hayden D.L., Beal M.F., Cudkowicz M.E. Riluzole therapy in Huntington's disease (HD). Mov. Disord. 14:1999;326-330.
16. Shoulson I., Fahn S. Huntington's disease: clinical care and evaluation. Neurology. 29:1979;1-3.
17. Starkstein S.E., Brandt J., Bylsma F., Peyser C., Folstein M., Folstein S.E. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology. 34:1992;487-489.
18. The Huntington Study Group. Unified Huntington's Disease rating scale: reliability and consistency, Mov. Disord. 11 (1996) 136-142.
19. The Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease, Neurology 50 (1998) 1366-1373.
20. 10 and remacemide in Huntington's disease, Neurology 57 (2001) 397-404.